Hypoxia in tumors is closely associated with tumor aggressiveness and resistance to radio- and chemotherapeutic treatment. Therefore, reliable markers for hypoxia represent both valuable diagnostic markers and potential targets for investigation.
When oxygen becomes limited, prolyl hydroxylase is inhibited which leads to HIF-α accumulation and translocation to the nucleus. HIF-α then dimerizes with HIF-β and interacts with cofactors such as p300/CBP and the Pol II complex to activate the hypoxia-response elements (HRE), which activate transcription of various genes including VEGFA, GLUT1, and CA9.
tebu-bio has selected a panel of primary antibodies related to this pathway.
A selection of 100% guaranteed research antibodies related to the Hypoxia pathway
- Anti HIF1: a rabbit polyclonal antibody to HIF1 alpha
- Anti VHL antibody: a rabbit polyclonal antibody to VHL
- Anti Heme Oxygenase 1 [N1C3]: a rabbit polyclonal antibody to Heme Oxygenase 1
- Anti EGLN2: a rabbit polyclonal antibody to EGLN2
- Anti FIH1: a rabbit monoclonal antibody (clone EPR3659) to FIH1
Looking for a specific intracellular pathway?
We strive to provide you regularly with new and updated pathways to support you in your research. If you are looking for a specific pathway, don’t hesitate to contact us.
[contact-form to=’myantibody@tebu-bio.com’ subject=’Pathway…’][contact-field label=’Nom’ type=’name’ required=’1’/][contact-field label=’Email’ type=’email’ required=’1’/][contact-field label=’Commentaire’ type=’textarea’ required=’1’/][/contact-form]
